These mutations showed additive effects with other gain-of-function mutants and affected the sensitivity and response to potentiators, highlighting the critical role of the TMD2 region in regulating CFTR activity and its potential as a therapeutic target for cystic fibrosis [255]. The gene discussed is CFTR; the disease is cystic fibrosis.